Clinical Report: FDA Greenlights Repeat Use of Glaukos’ iDose® TR

Overview

The FDA has approved the repeat administration of iDose® TR under defined conditions, allowing for enhanced treatment flexibility in glaucoma management. This decision is based on clinical evidence supporting the safety and tolerability of multiple uses of the device.

Background

The management of open-angle glaucoma and ocular hypertension often relies on topical medications, which can present adherence challenges such as forgetfulness and side effects. The introduction of sustained-release options like iDose TR addresses these concerns by providing continuous drug delivery. The FDA's approval for repeat use is significant, as it expands treatment options for patients while maintaining safety standards.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The FDA approved a labeling supplement for repeat administration of iDose TR.
• iDose TR is designed to deliver therapeutic levels of travoprost continuously for extended periods.
• Clinical studies, including Phase 2b and Phase 3 trials, showed no significant corneal endothelial cell loss after three years of use.
• The second administration of iDose TR was safe and well-tolerated over a 12-month evaluation period.
• iDose TR demonstrates a favorable long-term safety profile, enhancing its position in glaucoma treatment.

Clinical Implications

The approval for repeat use of iDose TR allows ophthalmologists to offer a more flexible treatment protocol for patients with glaucoma. This could improve patient adherence and outcomes by reducing the burden of daily topical medication regimens, potentially enhancing patient quality of life and reducing overall healthcare costs.

Conclusion

The FDA's endorsement of repeat administration for iDose TR marks a significant advancement in glaucoma therapy, reinforcing its safety and efficacy in managing intraocular pressure compared to traditional treatments.

Related Resources & Content

1. Ophthalmology Management, 2026 -- iDose TR Gains FDA Approval for Re-Treatment
2. Glaucoma Physician, 2026 -- FDA Allows Repeat Administration of iDose TR Recommendations
3. Ophthalmology Management, 2024 -- March 6
4. Glaucoma Physician, 2024 -- Permanent J-code Assigned for iDose TR Recommendations
5. AAO’s Updated PPP for POAG Emphasizes Individualized Monitoring
6. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial - PMC
7. Glaukos Announces US FDA Approval of NDA
8. AAO’s Updated PPP for POAG Emphasizes Individualized Monitoring
9. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial - PMC
10. Glaukos Announces US FDA Approval of NDA